Novo Nordisk A/S (NYSE:NVO) Shares Sold by Portside Wealth Group LLC

Portside Wealth Group LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,431 shares of the company’s stock after selling 584 shares during the quarter. Novo Nordisk A/S comprises about 0.9% of Portside Wealth Group LLC’s holdings, making the stock its 25th biggest holding. Portside Wealth Group LLC’s holdings in Novo Nordisk A/S were worth $5,026,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of NVO. Natixis Advisors LLC boosted its stake in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the period. Talbot Financial LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $4,066,000. Versant Capital Management Inc acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $86,000. Finally, Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $78.74 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The stock has a 50 day simple moving average of $97.76 and a 200-day simple moving average of $117.23.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.